{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:43:48Z","timestamp":1793940228905,"version":"4.8.0"},"reference-count":209,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jnci\/djx160","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T19:11:20Z","timestamp":1499281880000},"page":"14-30","source":"Crossref","is-referenced-by-count":213,"title":["Targeting Hypoxia to Improve Non\u2013Small Cell Lung Cancer Outcome"],"prefix":"10.1093","volume":"110","author":[{"given":"Ahmed","family":"Salem","sequence":"first","affiliation":[{"name":"Division of Cancer Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Asselin","sequence":"additional","affiliation":[{"name":"Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Reymen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO Lab), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lambin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO Lab), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine M L","family":"West","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P B","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"key\n\t\t\t\t20180315043333_djx160-B1","author":"International Agency for Research on Cancer"},{"issue":"9972","key":"key\n\t\t\t\t20180315043333_djx160-B2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","article-title":"Trends in incidence of small cell lung cancer and all lung cancer","volume":"75","author":"Riaz","year":"2012","journal-title":"Lung Cancer."},{"issue":"suppl 9","key":"key\n\t\t\t\t20180315043333_djx160-B4","doi-asserted-by":"crossref","first-page":"ix150","DOI":"10.1093\/annonc\/mdm311","article-title":"Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer","volume":"18","author":"Toschi","year":"2007","journal-title":"Ann Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B5","first-page":"w13855","article-title":"The expression of hypoxia-inducible factor-1alpha and its clinical significance in lung cancer: A systematic review and meta-analysis","volume":"143","author":"Ren","year":"2013","journal-title":"Swiss Med Wkly."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrc2540","article-title":"The impact of O2 availability on human cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semradonc.2014.11.006","article-title":"Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung","volume":"25","author":"Brustugun","year":"2015","journal-title":"Semin Radiat Oncol."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/0008-5472.CAN-15-2818","article-title":"Oxygen-enhanced MRI is a major advance in tumor hypoxia imaging","volume":"76","author":"Dewhirst","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B11","author":"Hansen"},{"key":"key\n\t\t\t\t20180315043333_djx160-B12","author":"Threshold Pharmaceuticals Inc"},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2012.171","article-title":"Imaging hypoxia to improve radiotherapy outcome","volume":"9","author":"Horsman","year":"2012","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2014.02.002","article-title":"The meaning, measurement and modification of hypoxia in the laboratory and the clinic","volume":"26","author":"Hammond","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"key\n\t\t\t\t20180315043333_djx160-B15","volume-title":"Radiobiology for the Radiologist","author":"Hall","year":"2006","edition":"6th ed."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"key\n\t\t\t\t20180315043333_djx160-B17","doi-asserted-by":"crossref","DOI":"10.1201\/b15450","volume-title":"Basic Clinical Radiobiology.","author":"Joiner","year":"2009","edition":"4th ed."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-14-0990","article-title":"Imaging intratumor heterogeneity: Role in therapy response, resistance, and clinical outcome","volume":"21","author":"O'Connor","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer."},{"issue":"11\u201312","key":"key\n\t\t\t\t20180315043333_djx160-B20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6690273","article-title":"Quantification of longitudinal tissue pO2 gradients in window chamber tumours: Impact on tumour hypoxia","volume":"79","author":"Dewhirst","year":"1999","journal-title":"Br J Cancer."},{"key":"key\n\t\t\t\t20180315043333_djx160-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/tumor-2012-0001","article-title":"Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors","volume":"1","author":"Koch","year":"2013","journal-title":"Tumor Microenviron Ther."},{"issue":"6692","key":"key\n\t\t\t\t20180315043333_djx160-B22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B23","first-page":"71","article-title":"Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3\/4 and SOX2","volume":"40","author":"Iida","year":"2012","journal-title":"Int J Oncol."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/jcb.22739","article-title":"Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells","volume":"111","author":"Liu","year":"2010","journal-title":"J Cell Biochem."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2011.03.014","article-title":"Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells","volume":"308","author":"Wohlkoenig","year":"2011","journal-title":"Cancer Lett."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B26","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1349-7006.2012.02408.x","article-title":"Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors","volume":"103","author":"Minakata","year":"2012","journal-title":"Cancer Sci."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B27","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.7314\/APJCP.2013.14.6.3607","article-title":"Prognostic role of hypoxic inducible factor expression in non-small cell lung cancer: A meta-analysis","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pac J Cancer Prev."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11596-016-1586-7","article-title":"Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: A systematic review with meta-analysis","volume":"36","author":"Yang","year":"2016","journal-title":"J Huazhong Univ Sci Technolog Med Sci."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JTO.0000000000000148","article-title":"Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer","volume":"9","author":"Stewart","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clon.2007.03.010","article-title":"Chemical radiosensitizers for use in radiotherapy","volume":"19","author":"Wardman","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"15","key":"key\n\t\t\t\t20180315043333_djx160-B31","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2011.40.8294","article-title":"Elusive goal of targeting tumor hypoxia for therapeutic gain","volume":"30","author":"Peters","year":"2012","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3816\/CLC.2010.n.042","article-title":"Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer","volume":"11","author":"Li","year":"2010","journal-title":"Clin Lung Cancer."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B33","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2967\/jnumed.109.069021","article-title":"Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer","volume":"50","author":"Lohith","year":"2009","journal-title":"J Nucl Med."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B34","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00259-009-1154-5","article-title":"Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA)","volume":"36","author":"Postema","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/1754-9485.12086","article-title":"Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy","volume":"57","author":"Trinkaus","year":"2013","journal-title":"J Med Imaging Radiat Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00259-015-3169-4","article-title":"Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: Quantification of tumour hypoxia, metabolism and perfusion","volume":"43","author":"van Elmpt","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s00259-015-3100-z","article-title":"Repeatability of hypoxia PET imaging using [(1)(8)F]HX4 in lung and head and neck cancer patients: A prospective multicenter trial","volume":"42","author":"Zegers","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.radonc.2013.08.031","article-title":"Hypoxia imaging with [(1)(8)F]HX4 PET in NSCLC patients: Defining optimal imaging parameters","volume":"109","author":"Zegers","year":"2013","journal-title":"Radiother Oncol."},{"issue":"26","key":"key\n\t\t\t\t20180315043333_djx160-B39","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: Adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2014.01.021","article-title":"Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer","volume":"111","author":"Arrieta","year":"2014","journal-title":"Radiother Oncol."},{"issue":"25","key":"key\n\t\t\t\t20180315043333_djx160-B41","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1200\/JCO.2005.08.011","article-title":"Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer","volume":"23","author":"Choy","year":"2005","journal-title":"J Clin Oncol."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B42","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/annonc\/mdv373","article-title":"A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: The Australasian Lung Cancer Trials Group NITRO Trial","volume":"26","author":"Davidson","year":"2015","journal-title":"Ann Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0169-5002(00)80087-2","article-title":"Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial","volume":"29","author":"Shepherd","year":"2000","journal-title":"Lung Cancer."},{"issue":"36","key":"key\n\t\t\t\t20180315043333_djx160-B44","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1200\/JCO.2005.01.3771","article-title":"Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003","volume":"23","author":"Williamson","year":"2005","journal-title":"J Clin Oncol."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2000.18.6.1351","article-title":"Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors","volume":"18","author":"von Pawel","year":"2000","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B46","author":"Loh"},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ijrobp.2007.04.008","article-title":"Phase I\/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002)","volume":"69","author":"Nishimura","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"18","key":"key\n\t\t\t\t20180315043333_djx160-B48","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B49","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/0360-3016(82)90292-9","article-title":"Misonidazole and radiotherapy in lung cancer: A randomized double-blind trial","volume":"8","author":"Mantyla","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1097-0142(19830701)52:1<20::AID-CNCR2820520105>3.0.CO;2-V","article-title":"Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung. A double-blind randomized trial","volume":"52","author":"Panduro","year":"1983","journal-title":"Cancer."},{"issue":"3\u20134","key":"key\n\t\t\t\t20180315043333_djx160-B51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0360-3016(82)90637-X","article-title":"A controlled clinical trial of misonidazole in the radiotherapy of patients with carcinoma of the bronchus","volume":"8","author":"Saunders","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B52","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/0360-3016(89)90953-X","article-title":"Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of an RTOG prospective randomized trial","volume":"16","author":"Simpson","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0360-3016(87)90100-3","article-title":"Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung: A phase III randomized trial of the RTOG. Radiation Therapy Oncology Group","volume":"13","author":"Simpson","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0360-3016(82)90532-6","article-title":"Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: Report of a phase I\/II trial","volume":"8","author":"Simpson","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt0512-381","article-title":"Hypoxia-activated prodrugs forge ahead in cancer","volume":"30","author":"Kling","year":"2012","journal-title":"Nat Biotechnol."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist Updat."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3892\/ijo.2015.3059","article-title":"Metronomic vinorelbine: Anti-angiogenic activity invitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition","volume":"47","author":"Mavroeidis","year":"2015","journal-title":"Int J Oncol."},{"issue":"9","key":"key\n\t\t\t\t20180315043333_djx160-B58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat Rev Cancer."},{"issue":"20","key":"key\n\t\t\t\t20180315043333_djx160-B59","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"Br J Cancer."},{"key":"key\n\t\t\t\t20180315043333_djx160-B61","doi-asserted-by":"crossref","first-page":"12308","DOI":"10.1038\/ncomms12308","article-title":"The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia","volume":"7","author":"Ashton","year":"2016","journal-title":"Nat Commun."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B62","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/pcan.2014.20","article-title":"A pilot \u2018window of opportunity\u2019 neoadjuvant study of metformin in localised prostate cancer","volume":"17","author":"Joshua","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12094-015-1412-x","article-title":"Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: A meta-analysis","volume":"18","author":"Tian","year":"2016","journal-title":"Clin Transl Oncol."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","author":"O'Connor","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-8140(02)00151-2","article-title":"Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant","volume":"64","author":"MacRae","year":"2002","journal-title":"Radiother Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B67","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0360-3016(00)00801-4","article-title":"Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival","volume":"48","author":"Werner-Wasik","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"key\n\t\t\t\t20180315043333_djx160-B68","first-page":"101","volume-title":"Blood Perfusion and Microenvironment of Human Tumors, Implications for Clinical Radiooncology.","author":"Grau","year":"1998"},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/jam.2007.0606","article-title":"Comparison of three carbon monoxide monitors for determination of smoking status in smokers and nonsmokers with and without COPD","volume":"20","author":"Christenhusz","year":"2007","journal-title":"J Aerosol Med."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B70","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2105\/AJPH.77.11.1435","article-title":"Comparison of tests used to distinguish smokers from nonsmokers","volume":"77","author":"Jarvis","year":"1987","journal-title":"Am J Public Health."},{"issue":"8","key":"key\n\t\t\t\t20180315043333_djx160-B71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B73","first-page":"311","article-title":"Radiation-induced vascular damage in tumors: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat","volume":"177","author":"Park","year":"2012","journal-title":"Res."},{"issue":"7","key":"key\n\t\t\t\t20180315043333_djx160-B74","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1118\/1.4730292","article-title":"A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC)","volume":"39","author":"Strigari","year":"2012","journal-title":"Med Phys."},{"issue":"13","key":"key\n\t\t\t\t20180315043333_djx160-B75","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1088\/0031-9155\/58\/13\/4611","article-title":"Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling","volume":"58","author":"Ruggieri","year":"2013","journal-title":"Phys Med Biol."},{"issue":"13","key":"key\n\t\t\t\t20180315043333_djx160-B76","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.prro.2013.12.002","article-title":"Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy","volume":"4","author":"Garg","year":"2014","journal-title":"Pract Radiat Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B80","doi-asserted-by":"crossref","first-page":"e010457","DOI":"10.1136\/bmjopen-2015-010457","article-title":"Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): A feasibility study","volume":"6","author":"Haslett","year":"2016","journal-title":"BMJ Open."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0167-8140(99)00106-1","article-title":"ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I\/II study by the EORTC","volume":"52","author":"Bernier","year":"1999","journal-title":"Radiother Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B82","author":"Reymen"},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2015.04.005","article-title":"IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma","volume":"116","author":"Hassan Metwally","year":"2015","journal-title":"Radiother Oncol."},{"issue":"24","key":"key\n\t\t\t\t20180315043333_djx160-B84","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/1078-0432.CCR-13-1787","article-title":"Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response","volume":"19","author":"Zannella","year":"2013","journal-title":"Clin Cancer Res."},{"key":"key\n\t\t\t\t20180315043333_djx160-B85","author":"Tsakiridis"},{"issue":"13","key":"key\n\t\t\t\t20180315043333_djx160-B86","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1158\/1078-0432.CCR-15-0018","article-title":"TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2012.08.019","article-title":"Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer","volume":"105","author":"Zips","year":"2012","journal-title":"Radiother Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2014.10.010","article-title":"Dynamics of tumor hypoxia assessed by 18F-FAZA PET\/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies","volume":"113","author":"Bollineni","year":"2014","journal-title":"Radiother Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B89","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0360-3016(95)00170-4","article-title":"Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography","volume":"33","author":"Koh","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1051","key":"key\n\t\t\t\t20180315043333_djx160-B90","doi-asserted-by":"crossref","first-page":"20150014","DOI":"10.1259\/bjr.20150014","article-title":"Validation of functional imaging as a biomarker for radiation treatment response","volume":"88","author":"Jentsch","year":"2015","journal-title":"Br J Radiol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B91","author":"Dubary"},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B92","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/0008-5472.CAN-15-2062","article-title":"Oxygen-enhanced MRI accurately identifies, quantifies, and maps tumor hypoxia in preclinical cancer models","volume":"76","author":"O'Connor","year":"2016","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t20180315043333_djx160-B93","volume-title":"Molecular imaging: Principles and practice.","author":"Weissleder","year":"2010"},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B94","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s00259-015-3100-z","article-title":"Repeatability of hypoxia PET imaging using [(18)F]HX4 in lung and head and neck cancer patients: A prospective multicenter trial","volume":"42","author":"Zegers","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B95","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13550-016-0210-y","article-title":"Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer","volume":"6","author":"Grkovski","year":"2016","journal-title":"EJNMMI Res."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2009.03.006","article-title":"Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan","volume":"91","author":"Aerts","year":"2009","journal-title":"Radiother Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B97","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2015.07.013","article-title":"PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes","volume":"116","author":"Even","year":"2015","journal-title":"Radiother Oncol."},{"issue":"24","key":"key\n\t\t\t\t20180315043333_djx160-B98","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-14-1524","article-title":"In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET\/CT imaging","volume":"20","author":"Zegers","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"7","key":"key\n\t\t\t\t20180315043333_djx160-B99","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.109.062638","article-title":"Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI","volume":"50","author":"Dirix","year":"2009","journal-title":"J Nucl Med."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.radonc.2007.05.014","article-title":"Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer","volume":"83","author":"Eschmann","year":"2007","journal-title":"Radiother Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2012.09.015","article-title":"FAZA PET\/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial","volume":"105","author":"Mortensen","year":"2012","journal-title":"Radiother Oncol."},{"issue":"8","key":"key\n\t\t\t\t20180315043333_djx160-B102","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00259-014-2730-x","article-title":"A prospective clinical study of (1)(8)F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy","volume":"41","author":"Servagi-Vernat","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"key\n\t\t\t\t20180315043333_djx160-B103","doi-asserted-by":"crossref","first-page":"1):109","DOI":"10.1016\/j.radonc.2010.10.011","article-title":"Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study","volume":"98","author":"Vera","year":"2011","journal-title":"Radiother Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2008.10.049","article-title":"Prospective trial incorporating pre-\/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy","volume":"75","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-8140(95)01622-N","article-title":"Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma","volume":"37","author":"Levine","year":"1995","journal-title":"Radiother Oncol."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B106","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1054\/bjoc.1999.1059","article-title":"Pretreatment apoptosis in carcinoma of the cervix correlates with changes in tumour oxygenation during radiotherapy","volume":"82","author":"Sheridan","year":"2000","journal-title":"Br J Cancer."},{"issue":"24","key":"key\n\t\t\t\t20180315043333_djx160-B107","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-15-0290","article-title":"Preclinical assessment of efficacy of radiation dose painting based on intratumoral FDG-PET uptake","volume":"21","author":"Trani","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B108","first-page":"271","article-title":"Implementation of hypoxia PET imaging in radiation therapy planning","volume":"57","author":"Geets","year":"2013","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B109","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/annonc\/mdv370","article-title":"A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170) dagger","volume":"26","author":"Dingemans","year":"2015","journal-title":"Ann Oncol."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B110","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","article-title":"Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer","volume":"18","author":"Sun","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"9","key":"key\n\t\t\t\t20180315043333_djx160-B111","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-10-3425","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies","volume":"17","author":"Weiss","year":"2011","journal-title":"Clin Cancer Res."},{"key":"key\n\t\t\t\t20180315043333_djx160-B112","author":"Threshold Media Inquiries"},{"issue":"14_suppl","key":"key\n\t\t\t\t20180315043333_djx160-B113","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1200\/jco.2004.22.14_suppl.7115","article-title":"Standard whole brain radiation (WBRT) with supplemental oxygen (O2) with or without RSR13 (efaproxiral) in patients with brain metastases originating from NSCLC: Results of a subgroup analysis","volume":"22","author":"Nabid","year":"2004","journal-title":"J Clin Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11307-016-0994-1","article-title":"Quantitative [18F]FMISO PET imaging shows reduction of hypoxia following trastuzumab in a murine model of HER2+ breast cancer","volume":"19","author":"Sorace","year":"2017","journal-title":"Mol Imaging Biol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B115","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijrobp.2016.01.035","article-title":"Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality","volume":"95","author":"Jiang","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"21","key":"key\n\t\t\t\t20180315043333_djx160-B116","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.4161\/cbt.8.21.9988","article-title":"Modulating the tumor microenvironment to increase radiation responsiveness","volume":"8","author":"Karar","year":"2009","journal-title":"Cancer Biol Ther."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B117","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.radonc.2013.05.006","article-title":"Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment","volume":"108","author":"Nijkamp","year":"2013","journal-title":"Radiother Oncol."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B118","doi-asserted-by":"crossref","first-page":"e86459","DOI":"10.1371\/journal.pone.0086459","article-title":"Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor","volume":"9","author":"Murakami","year":"2014","journal-title":"PLoS One."},{"issue":"23","key":"key\n\t\t\t\t20180315043333_djx160-B119","doi-asserted-by":"crossref","first-page":"22473","DOI":"10.1074\/jbc.M500963200","article-title":"Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase\/PTEN\/AKT\/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha","volume":"280","author":"Phillips","year":"2005","journal-title":"J Biol Chem."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1533034615574386","article-title":"Tumor hypoxia response after targeted therapy in EGFR-mutant non-small cell lung cancer: Proof of concept for FMISO-PET","volume":"15","author":"Arvold","year":"2016","journal-title":"Technol Cancer Res Treat."},{"issue":"16","key":"key\n\t\t\t\t20180315043333_djx160-B121","first-page":"5055","article-title":"Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system invitro and invivo","volume":"50","author":"Herman","year":"1990","journal-title":"Cancer Res."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B122","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jnci\/84.3.187","article-title":"Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma","volume":"84","author":"Holden","year":"1992","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"key\n\t\t\t\t20180315043333_djx160-B124","author":"FDA-NIH Biomarker Working Group","year":"2016"},{"issue":"1035","key":"key\n\t\t\t\t20180315043333_djx160-B125","doi-asserted-by":"crossref","first-page":"20130676","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br J Radiol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-3023-4_23","volume-title":"Oxygen Transport to Tissue XXXVII.","author":"Epel","year":"2016"},{"key":"key\n\t\t\t\t20180315043333_djx160-B127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-319-38810-6_13","article-title":"Direct and repeated clinical measurements of pO2 for enhancing cancer therapy and other applications","volume":"923","author":"Swartz","year":"2016","journal-title":"Adv Exp Med Biol."},{"issue":"13","key":"key\n\t\t\t\t20180315043333_djx160-B128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","article-title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study","volume":"15","author":"Lalonde","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"key\n\t\t\t\t20180315043333_djx160-B129","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.mri.2012.06.009","article-title":"Promise and pitfalls of quantitative imaging in oncology clinical trials","volume":"30","author":"Kurland","year":"2012","journal-title":"Magn Reson Imaging."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/0284186X.2017.1287943","article-title":"Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy","volume":"56","author":"Di Perri","year":"2017","journal-title":"Acta Oncol."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B131","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","author":"O'Connor","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"7329","key":"key\n\t\t\t\t20180315043333_djx160-B132","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B133","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"key\n\t\t\t\t20180315043333_djx160-B134","author":"Becquerel"},{"key":"key\n\t\t\t\t20180315043333_djx160-B135","author":"Higgins"},{"key":"key\n\t\t\t\t20180315043333_djx160-B136","author":"Kong"},{"key":"key\n\t\t\t\t20180315043333_djx160-B137","author":"Williams"},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B138","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2012.196","article-title":"Predicting outcomes in radiation oncology\u2014multifactorial decision support systems","volume":"10","author":"Lambin","year":"2013","journal-title":"Nat Rev Clin Oncol."},{"issue":"7","key":"key\n\t\t\t\t20180315043333_djx160-B139","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"key\n\t\t\t\t20180315043333_djx160-B140","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-06-3322","article-title":"Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers","volume":"67","author":"Winter","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B141","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/14756366.2014.966704","article-title":"Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA consortium","volume":"30","author":"Pettersen","year":"2015","journal-title":"J Enzyme Inhib Med Chem."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B142","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/sj.bjc.6605450","article-title":"Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene","volume":"102","author":"Buffa","year":"2010","journal-title":"Br J Cancer."},{"issue":"17","key":"key\n\t\t\t\t20180315043333_djx160-B143","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1158\/1078-0432.CCR-13-0542","article-title":"A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer","volume":"19","author":"Eustace","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B144","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semradonc.2011.12.006","article-title":"Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy","volume":"22","author":"Toustrup","year":"2012","journal-title":"Semin Radiat Oncol."},{"issue":"17","key":"key\n\t\t\t\t20180315043333_djx160-B145","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-11-1182","article-title":"Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer","volume":"71","author":"Toustrup","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B146","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2012.07.028","article-title":"Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma","volume":"49","author":"Betts","year":"2013","journal-title":"Eur J Cancer."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B147","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.radonc.2016.04.024","article-title":"Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer \u2013 a survival model with external validation","volume":"119","author":"Carvalho","year":"2016","journal-title":"Radiother Oncol."},{"issue":"9","key":"key\n\t\t\t\t20180315043333_djx160-B148","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/JTO.0b013e3181ae2844","article-title":"Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004","volume":"4","author":"Isa","year":"2009","journal-title":"J Thorac Oncol."},{"issue":"29","key":"key\n\t\t\t\t20180315043333_djx160-B149","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1200\/JCO.2008.17.0662","article-title":"Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003","volume":"26","author":"Mack","year":"2008","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B150","first-page":"3513","article-title":"The association between osteopontin and survival in non-small-cell lung cancer patients: A meta-analysis of 13 cohorts","volume":"8","author":"Wang","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B151","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.bjc.6605690","article-title":"High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer","volume":"102","author":"Ilie","year":"2010","journal-title":"Br J Cancer."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B152","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-11-2295","article-title":"Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial","volume":"18","author":"Lim","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B153","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(05)70292-8","article-title":"Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial","volume":"6","author":"Overgaard","year":"2005","journal-title":"Lancet Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B154","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1128\/MCB.01395-06","article-title":"A microRNA signature of hypoxia","volume":"27","author":"Kulshreshtha","year":"2007","journal-title":"Mol Cell Biol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B155","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1038\/cddis.2013.71","article-title":"MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines","volume":"4","author":"Grosso","year":"2013","journal-title":"Cell Death Dis."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B156","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2013.11.005","article-title":"Positive prognostic impact of miR-210 in non-small cell lung cancer","volume":"83","author":"Eilertsen","year":"2014","journal-title":"Lung Cancer."},{"key":"key\n\t\t\t\t20180315043333_djx160-B157","doi-asserted-by":"crossref","first-page":"316745","DOI":"10.1155\/2015\/316745","article-title":"Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma","volume":"2015","author":"Osugi","year":"2015","journal-title":"J Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B158","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/0300060513497560","article-title":"Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer","volume":"41","author":"Li","year":"2013","journal-title":"J Int Med Res."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B159","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/jcm4101890","article-title":"Circulating microRNA biomarkers as liquid biopsy for cancer patients: Pros and cons of current assays","volume":"4","author":"Ono","year":"2015","journal-title":"J Clin Med."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B160","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00259-003-1130-4","article-title":"In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM","volume":"30","author":"Dehdashti","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B161","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02988690","article-title":"Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer","volume":"14","author":"Takahashi","year":"2000","journal-title":"Ann Nucl Med."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B162","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0360-3016(89)90146-6","article-title":"Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia","volume":"17","author":"Rasey","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B163","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"key\n\t\t\t\t20180315043333_djx160-B164","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2015.11.020","article-title":"Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer","volume":"91","author":"Kinoshita","year":"2016","journal-title":"Lung Cancer."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B165","first-page":"253","article-title":"Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy","volume":"46","author":"Eschmann","year":"2005","journal-title":"J Nucl Med."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B166","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/cas.12771","article-title":"Prognostic value of (18) F-fluoroazomycin arabinoside PET\/CT in patients with advanced non-small-cell lung cancer","volume":"106","author":"Saga","year":"2015","journal-title":"Cancer Sci."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B167","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2967\/jnumed.114.141846","article-title":"Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients","volume":"55","author":"Verwer","year":"2014","journal-title":"J Nucl Med."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B168","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00259-013-2462-3","article-title":"Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients","volume":"40","author":"Verwer","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13550-016-0187-6","article-title":"An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET\/CT in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"6","author":"Kerner","year":"2016","journal-title":"EJNMMI Res."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/mrm.23014","article-title":"Dynamic contrast-enhanced-MRI of tumor hypoxia","volume":"67","author":"Egeland","year":"2012","journal-title":"Magn Reson Med."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B171","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.radonc.2011.11.013","article-title":"Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging","volume":"102","author":"Ovrebo","year":"2012","journal-title":"Radiother Oncol."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B172","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/09553000601002324","article-title":"Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy","volume":"82","author":"Tatum","year":"2006","journal-title":"Int J Radiat Biol."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B173","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ijrobp.2008.12.040","article-title":"Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: A potential novel biomarker of oxygenation changes in solid tumors","volume":"75","author":"O'Connor","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B174","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/mrm.24826","article-title":"Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma","volume":"71","author":"Linnik","year":"2014","journal-title":"Magn Reson Med."},{"key":"key\n\t\t\t\t20180315043333_djx160-B175","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-12-496","article-title":"PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours","volume":"12","author":"McKeage","year":"2012","journal-title":"BMC Cancer."},{"key":"key\n\t\t\t\t20180315043333_djx160-B176","author":"Lau"},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B177","first-page":"4356","article-title":"Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: A california cancer consortium phase I and molecular correlative study","volume":"9","author":"Lara","year":"2003","journal-title":"Clin Cancer Res."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B178","first-page":"31","article-title":"Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks","volume":"3","author":"Senan","year":"1997","journal-title":"Clin Cancer Res."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B179","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.1997.15.2.773","article-title":"Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3\u2009weeks in patients with solid tumors","volume":"15","author":"Johnson","year":"1997","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180315043333_djx160-B180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3816\/CLC.2005.n.008","article-title":"Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: A phase I\/II study","volume":"6","author":"Gatineau","year":"2005","journal-title":"Clin Lung Cancer."},{"issue":"21","key":"key\n\t\t\t\t20180315043333_djx160-B181","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1158\/1078-0432.CCR-08-0483","article-title":"A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies","volume":"14","author":"Papadopoulos","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B182","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jnci\/86.12.906","article-title":"Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09","volume":"86","author":"Schellens","year":"1994","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B183","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00280-015-2693-z","article-title":"Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors","volume":"75","author":"Hyman","year":"2015","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B184","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-2004-830056","article-title":"Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]","volume":"58","author":"Reck","year":"2004","journal-title":"Pneumologie."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B185","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1200\/JCO.1998.16.11.3524","article-title":"Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study","volume":"16","author":"Treat","year":"1998","journal-title":"J Clin Oncol."},{"issue":"12","key":"key\n\t\t\t\t20180315043333_djx160-B186","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1023\/A:1008219125746","article-title":"Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"8","author":"Miller","year":"1997","journal-title":"Ann Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B187","author":"Pearce"},{"key":"key\n\t\t\t\t20180315043333_djx160-B188","author":"Bhatt"},{"key":"key\n\t\t\t\t20180315043333_djx160-B189","author":"Proacta Incorporated"},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2014.01.001","article-title":"Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB\/IV non-small cell lung cancer (NSCLC)","volume":"83","author":"Reinmuth","year":"2014","journal-title":"Lung Cancer."},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B191","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.2005.04.0436","article-title":"Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB\/IV non-small-cell lung cancer","volume":"24","author":"Yasuda","year":"2006","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20180315043333_djx160-B192","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/174_2011_278","volume-title":"Advances in Radiation Oncology in Lung Cancer.","author":"Brade","year":"2011"},{"issue":"4","key":"key\n\t\t\t\t20180315043333_djx160-B193","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1269\/jrr.46.453","article-title":"Reevaluation of the radiosensitizing effects of sanazole and nimorazole invitro and invivo","volume":"46","author":"Sugie","year":"2005","journal-title":"J Radiat Res."},{"issue":"3","key":"key\n\t\t\t\t20180315043333_djx160-B194","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2008.03.002","article-title":"Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole","volume":"87","author":"Murata","year":"2008","journal-title":"Radiother Oncol."},{"issue":"2","key":"key\n\t\t\t\t20180315043333_djx160-B195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5732\/cjc.012.10285","article-title":"Bioreductive prodrugs as cancer therapeutics: Targeting tumor hypoxia","volume":"33","author":"Guise","year":"2014","journal-title":"Chin J Cancer."},{"issue":"10","key":"key\n\t\t\t\t20180315043333_djx160-B196","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","article-title":"AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia","volume":"126","author":"Moradi Manesh","year":"2015","journal-title":"Blood."},{"issue":"6","key":"key\n\t\t\t\t20180315043333_djx160-B197","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clon.2007.03.006","article-title":"Bioreductive drugs: From concept to clinic","volume":"19","author":"McKeown","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"8","key":"key\n\t\t\t\t20180315043333_djx160-B198","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1054\/bjoc.2001.2056","article-title":"A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9","volume":"85","author":"Choudry","year":"2001","journal-title":"Br J Cancer."},{"issue":"11","key":"key\n\t\t\t\t20180315043333_djx160-B199","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/0959-8049(96)00226-2","article-title":"EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group","volume":"32a","author":"Dirix","year":"1996","journal-title":"Eur J Cancer."},{"key":"key\n\t\t\t\t20180315043333_djx160-B200","doi-asserted-by":"crossref","first-page":"659723","DOI":"10.1155\/2013\/659723","article-title":"Evaluation of diabetic patients with breast cancer treated with metformin during adjuvant radiotherapy","volume":"2013","author":"Ferro","year":"2013","journal-title":"Int J Breast Cancer."},{"issue":"1","key":"key\n\t\t\t\t20180315043333_djx160-B201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijrobp.2010.03.005","article-title":"Ionizing radiation activates AMP-activated kinase (AMPK): A target for radiosensitization of human cancer cells","volume":"78","author":"Sanli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"key\n\t\t\t\t20180315043333_djx160-B202","author":"Rimner"},{"key":"key\n\t\t\t\t20180315043333_djx160-B203","author":"Roa"},{"key":"key\n\t\t\t\t20180315043333_djx160-B204","author":"Vera"},{"key":"key\n\t\t\t\t20180315043333_djx160-B205","author":"Salem"},{"key":"key\n\t\t\t\t20180315043333_djx160-B206","author":"Higgins"},{"key":"key\n\t\t\t\t20180315043333_djx160-B207","author":"Perkins"},{"issue":"13","key":"key\n\t\t\t\t20180315043333_djx160-B208","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","article-title":"Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02","volume":"24","author":"Rischin","year":"2006","journal-title":"J Clin Oncol."},{"issue":"9","key":"key\n\t\t\t\t20180315043333_djx160-B209","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2967\/jnumed.112.118083","article-title":"Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer","volume":"54","author":"Thureau","year":"2013","journal-title":"J Nucl Med."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/110\/1\/14\/24367642\/djx160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T16:20:20Z","timestamp":1602433220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/110\/1\/14\/4096546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":209,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,8,28]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djx160","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,8,28]]}}}